Valuation dashboard for Xenon Pharmaceuticals Inc. (XENE) with P/E N/A, P/B 3.00, EV/EBITDA -8.43 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy.
Analysis Summary
Xenon Pharmaceuticals Inc. reported revenue of $7.5M in the most recent fiscal year, growing at a 5-year CAGR of -25.3%.
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At $37.41 (closing price, October 30, 2026), XENE has negative trailing earnings (P/E not meaningful) and an ROE of -43.98%. Market capitalisation stands at $3.6B.
Balance sheet quality for XENE: current ratio of 13.4. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 3.00 |
| EV / EBITDA | -8.43 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $2.44 |
| vs Current Price | -93.5% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. | $3.6B | 3.00 | -44.0% | |
| NBIX | Neurocrine Biosciences, Inc. | $14.9B | 21.42 | 4.00 | 21.1% |
| JAZZ | Jazz Pharmaceuticals plc | $14.0B | 14.76 | 2.84 | 21.4% |
| AXSM | Axsome Therapeutics, Inc. | $7.6B | 89.29 | -255.6% | |
| PRAX | Praxis Precision Medicines, Inc. | $8.0B | 6.21 | -34.1% | |
| ACAD | Acadia Pharmaceuticals Inc. | $3.5B | 9.27 | 2.70 | 32.4% |
| DNLI | Denali Therapeutics Inc. | $3.0B | 4.25 | -55.3% | |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.4B | 2.30 | -4.1% |
Price
| Price | $37.41 (closing price, October 30, 2026) |
| Market Cap | $3.6B |
| Exchange | NASDAQ |
| Country | CA |
Profitability
| Return on Equity | -43.98% |
| Return on Invested Capital | -35.10% |
| Return on Assets | -31.58% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: NBIX · JAZZ · AXSM · PRAX · ACAD · DNLI · SUPN
Explore sector: Healthcare · Biotechnology
More sections of XENE: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks